Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19

WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased

Read more

GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial

TAMPA, Florida, April 8, 2019 /CNW/ –GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on

Read more

Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0

REHOVOT, Israel and NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics

Read more

Interview: CEO Allen Davidoff of XORTX Therapeutics Inc.(OTCQB: XRTXF)

CEO Allen Davidoff of XORTX Therapeutics Inc., talks about their focus of developing therapies for kidney disease, diabetic nephropathy, and cardiovascular disease.

Read more

CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it

Read more

Featured Interview: CEO John Huemoeller of Axim Biotechnologies, Inc. (OTCQB: AXIM)

CEO John Huemoeller of Axim Biotechnologies, Inc., talks about becoming the new CEO, how his business background will help in executing the new business plan, and bringing new pharmaceutical products to market.

Read more

Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound In Second Pre-Clinical Study For Non-Alcoholic Fatty Liver Disease

VANCOUVER, British Columbia, Jan. 21, 2019 (GLOBE NEWSWIRE) — Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH)

Read more

UPDATE–CTT Pharmaceutical Holdings, Inc., (CTTH) Announces Canadian Patent for Orally Administrable Nanonized Cannabinoids, Opioids and Other Pharmaceutical Agents

HAMILTON, Ontario, (Uptick Newswire – February 21, 2018) — CTT Pharmaceutical Holdings, Inc., (OTC:CTTH), an innovative life sciences company with

Read more